Grand Opening Celebration to officially open the doors of 7070 Mississauga Road
MISSISSAUGA, ON, Oct. 2, 2013 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) celebrated today the Grand Opening of its new pharmaceutical headquarters at 7070 Mississauga Road. Employees will start moving into the newly renovated offices immediately. The celebration was hosted by Ronnie Miller, President and CEO of Roche Canada, who was joined by special guest, Dr. Franz Humer, Chairman of the Board of Directors of Roche Holding Ltd., colleagues from Roche Canada, as well as members of all levels of government, including the government of Switzerland.
"This is a very exciting day for Roche Canada as we move into a building that is truly representative of our company and our future - bright, energetic and collaborative," explained Ronnie Miller, President and CEO, Roche Canada. "I am thrilled to welcome so many people to our corporate house-warming."
Roche Canada's pharmaceutical division, previously located at 2455 Meadowpine Blvd. in Mississauga, employs 621 people in Canada, 500 (full time, permanent) of whom are based in the head office in Mississauga.
Roche In Canada
Roche Canada's pharmaceutical and diagnostics divisions have generated more than $1 billion in total economic activity and have supported 4,786 jobs both directly and indirectly across Canada over the past two years.
Hoffmann-La Roche Limited was founded in Montreal, Quebec in 1931.
Roche Diagnostics Canada remains in Quebec, with its head office based in Laval. In 2001, as a result of significant growth, Roche Diagnostics Canada doubled its warehouse facility and, in 2007, invested $20 million to renovate and expand its office building.
The pharmaceutical headquarters remained in Quebec until 1983, when it moved to the Greater Toronto Area (GTA). First located in Etobicoke, Roche Pharmaceuticals moved to Meadowpine Blvd. in Mississauga in 1990.
In 2011, Roche Pharmaceuticals announced a significant expansion with the introduction of a Global Pharmaceutical Development site, which plays a leadership role in worldwide clinical trials. The project involved an investment by Roche of more than $190 million in Ontario, and has resulted in a growth from 76 to 236 people in Pharmaceutical Development since the announcement. The expansion project is supported by a $7.79 million investment from the Government of Ontario, and reflects the shared commitment of Roche and the Government of Ontario to build long-term prosperity and international leadership in life sciences and biopharmaceuticals in the province.
On October 2, Roche Canada's Pharmaceutical division opened the doors to a brand new facility at 7070 Mississauga Road, Ontario, relocating its employees to a facility that is updated, vibrant, fosters collaboration and teamwork, and is reflective of Roche's truly innovative culture.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
SOURCE: Hoffmann-La Roche Limited (Roche Canada)
For further information:
Manager, Corporate Relations